Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seltorexant - Janssen Pharmaceuticals/Minerva Neurosciences

Next Previous
Drug Profile

Seltorexant - Janssen Pharmaceuticals/Minerva Neurosciences

Alternative Names: JNJ-42847922; JNJ-7922; MIN-202

Latest Information Update: 14 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Minerva Neurosciences
  • Class Antidepressants; Ketones; Pyrimidines; Pyrroles; Sleep disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Insomnia; Major depressive disorder
  • Phase I Sleep apnoea syndrome

Most Recent Events

  • 19 Jan 2019 Janssen Research & Development completes a phase II trial in Major depressive disorder (Adjunctive treatment) in Bulgaria, Finland, France, Russia, Ukraine, Germany, USA, Japan (PO) (NCT03227224)
  • 10 Jan 2019 Phase II development is ongoing for Major depressive disorder (Adjunctive treatment) in Germany and Japan (PO) (NCT03227224)
  • 04 Jan 2019 Phase-I clinical trials in Sleep apnoea syndrome in USA (PO) (NCT03796026)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top